Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedBiomarker/Laboratory analysis, TreatmentClosed18 and overNCI, OtherJ05115, CDR0000491987
P30CA006973, JHOC-J05115, NCT00361296

Trial Description


RATIONALE: Vaccines made from cancer cells may help the body build an effective immune response to kill abnormal cells.

PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients with myelodysplastic syndromes (MDS).

Further Study Information



  • Determine the safety of GM-K562 cell vaccine in patients with myelodysplastic syndromes.
  • Determine the hematologic and cytogenetic response in patients treated with this vaccine.


  • Determine if vaccination with GM-K562 cell vaccine can induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3), as defined by a 30% increase from baseline in specific cytotoxic T-cells measured by Elispot assay, in patients with myelodysplastic syndromes.
  • Determine if immune response correlates with any clinical responses (e.g., hematologic response, resolution of cytogenetic abnormalities, or decrease in other parameters, such as WT-1 mRNA levels).

OUTLINE: This is an open-label study.

Patients receive GM-K562 cell vaccine subcutaneously once in weeks 0, 3, 6, 9, and 17 in the absence of disease progression or unacceptable toxicity.

Blood and tissue samples are collected periodically for correlative and biomarker studies. Samples are analyzed by cytogenetic studies, fluorescent in situ hybridization (FISH), and flow cytometry. Elispot is used to quantify cellular cytotoxic T-cell response to Wilms' tumor-1 (WT-1), survivin, and proteinase 3.

After completion of study treatment, patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.

Eligibility Criteria


  • Pathologically confirmed myelodysplastic syndromes (MDS), including any of the following:
  • Refractory anemia (RA)
  • RA with ringed sideroblasts
  • Refractory cytopenias with multilineage dysplasia (RCMD)
  • RCMD with ringed sideroblasts
  • RA with excess blasts 1 (5-9% blasts)
  • RA with excess blasts 2 (10-19% blasts)
  • Must have poor-risk MDS, defined by the following:
  • At least 2 lineages involved
  • Unfavorable cytogenetics (i.e., abnormalities of chromosome 5 or 7, 11q23, t[6;9], trisomy 8, inv3, or multiple/complex karyotype)
  • Transfusion requirement of > 2 units of packed red blood cells monthly
  • No chronic myelomonocytic leukemia
  • No transformation to acute myeloid leukemia


  • ECOG performance status 0-2
  • Creatinine < 2.5 mg/dL
  • Bilirubin < 2.5 mg/dL (unless due to Gilbert's syndrome)
  • Room air oxygen saturation ≥ 94% at rest
  • Fertile patients must use effective contraception
  • Negative pregnancy test
  • No other malignancy within the past 5 years except in situ cervical cancer or adequately treated nonmelanoma skin cancer
  • No active autoimmune disease or history of autoimmune disease requiring systemic immunosuppressants including, but not limited to, any of the following:
  • Autoimmune hemolytic anemia
  • Idiopathic thrombocytopenia purpura
  • Inflammatory bowel disease
  • Vasculitis
  • Thyroiditis
  • Rheumatic illnesses
  • No known HIV serum antibody positivity
  • No other disease requiring long-term corticosteroids or other immunosuppressants, such as severe chronic obstructive pulmonary disease or asthma


  • At least 2 weeks since prior systemic corticosteroids or other immunosuppressants (e.g., cyclosporine, azathioprine, tacrolimus, or mycophenolate mofetil)
  • At least 3 weeks since prior growth factors
  • At least 2 months since prior azacitidine for MDS
  • No prior bone marrow or other organ transplantation
  • No concurrent cytotoxic-based therapy for MDS
  • No other concurrent growth factors, including epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)

Trial Contact Information

Trial Lead Organizations/Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

  • National Cancer Institute
B. Douglas Smith, Principal Investigator

Link to the current record.
NLM Identifier NCT00361296 processed this data on April 09, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to